Payment overview · 2025
General Payments
$5,285.12
206 reported records · 48 companies
Healthcare provider profile · identity verified
Kimberly Hageman Merrill, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · JOHNSON CITY, NY · NPI 1225325921
Verified facts
What the public records show
CMS Open Payments records show Kimberly Hageman Merrill, NP-C received $5,285.12 in general payments during 2025 across 206 reported records.
PFIZER INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 99 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bosulif, Calquence, Eliquis, Imbruvica, Jakafi, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Bosulif by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 3017 records involving 2109 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Bosulif by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $928.17 | 17.6% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $416.98 | 7.9% | 20 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $398.83 | 7.5% | 21 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $227.99 | 4.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $224.20 | 4.2% | 11 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $191.91 | 3.6% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $188.37 | 3.6% | 11 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $185.75 | 3.5% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $177.93 | 3.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $171.17 | 3.2% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $170.62 | 3.2% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $162.44 | 3.1% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $154.62 | 2.9% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.59 | 2.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.31 | 2.2% | 6 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $113.42 | 2.1% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $95.08 | 1.8% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $93.33 | 1.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.71 | 1.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.36 | 1.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $75.44 | 1.4% | 3 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $66.54 | 1.3% | 4 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $62.03 | 1.2% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $52.10 | 1.0% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $50.42 | 0.9% | 2 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $49.97 | 0.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $49.66 | 0.9% | 3 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $47.97 | 0.9% | 3 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $42.15 | 0.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.81 | 0.7% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $38.24 | 0.7% | 2 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $37.88 | 0.7% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $36.74 | 0.7% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $35.42 | 0.7% | 2 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $34.43 | 0.7% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $27.93 | 0.5% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.79 | 0.5% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $26.14 | 0.5% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $21.99 | 0.4% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $21.95 | 0.4% | 1 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $21.42 | 0.4% | 1 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.83 | 0.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.03 | 0.3% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $16.62 | 0.3% | 1 | 2025 |
| Helsinn Therapeutics (U.S.), Inc. | Unresolved — no canonical attribution shown | $15.80 | 0.3% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $14.18 | 0.3% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.86 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,367.12 | 203 |
| Consulting Fee | $720.00 | 1 |
| Education | $198.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $757.19 | 3 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $250.11 | 5 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $248.45 | 14 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $236.95 | 13 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $171.17 | 7 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $170.62 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $162.44 | 5 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $160.93 | 10 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $129.75 | 4 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $128.23 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $119.59 | 5 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $115.31 | 6 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $106.29 | 5 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $95.97 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $86.67 | 4 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $85.71 | 3 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $85.71 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $85.22 | 6 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $84.36 | 4 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $81.69 | 4 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $80.51 | 5 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $75.44 | 3 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $71.81 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $70.95 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $67.68 | 4 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $67.68 | 4 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $66.54 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.07 | 4 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $62.03 | 3 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $61.70 | 3 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $59.21 | 2 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.80 | 3 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $56.32 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $55.02 | 3 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $50.42 | 2 | 2025 |
Source payment records
|
|||||
| AXTLE Normalized: axtle |
Drug | AVYXA PHARMA, LLC | $49.97 | 2 | 2025 |
Source payment records
|
|||||
| DOCIVYX Normalized: docivyx |
Drug | AVYXA PHARMA, LLC | $49.97 | 2 | 2025 |
Source payment records
|
|||||
| POSFREA Normalized: posfrea |
Drug | AVYXA PHARMA, LLC | $49.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $49.58 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $48.91 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $47.97 | 3 | 2025 |
Source payment records
|
|||||
| RUBRACA Normalized: rubraca |
Drug | TOLMAR, INC., pharmaand GmbH | $46.75 | 3 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $46.56 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $42.15 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $40.30 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $36.74 | 2 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $34.43 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $30.06 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $29.88 | 1 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| FRINDOVYX Normalized: frindovyx |
Drug | AVYXA PHARMA, LLC | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| LUTRATE DEPOT Normalized: lutrate depot |
Drug | AVYXA PHARMA, LLC | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| Alecensa Normalized: alecensa |
Biological | Genentech USA, Inc. | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| CYCLOPHOSPHAMIDE Normalized: cyclophosphamide |
Drug | AVYXA PHARMA, LLC | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ALPROLIX Normalized: alprolix |
Biological | GENZYME CORPORATION | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| ALTUVIIIO Normalized: altuviiio |
Biological | GENZYME CORPORATION | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| QFITLIA Normalized: qfitlia |
Drug | GENZYME CORPORATION | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| MYRISK Normalized: myrisk |
Device | Myriad Genetic Laboratories, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| AKYNZEO Normalized: akynzeo |
Drug | Helsinn Therapeutics (U.S.), Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Optune Gio Normalized: optune gio |
Device | Novocure Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $11.89 | 1 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $8.19 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $8.19 | 1 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $8.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOSULIF bosulif |
2025 | Bosulif | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CALQUENCE calquence |
2025 | Calquence | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1228863907 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 31 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 31 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 3017 supporting records · 2109 recipient NPIs · example record 1228795613 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 150 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 131 | 28 |
| Eliquis | Apixaban | 106 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 26 |
| Revlimid | Lenalidomide | 75 | 13 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 71 | 45 |
| Gabapentin | Gabapentin | 69 | 23 |
| Abiraterone Acetate | Abiraterone Acetate | 67 | 13 |
| Letrozole | Letrozole | 62 | 23 |
| Dexamethasone | Dexamethasone | 61 | 31 |
| Prednisone | Prednisone | 61 | 35 |
| Imbruvica | Ibrutinib | 59 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 58 | 18 |
| Pomalyst | Pomalidomide | 58 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 55 | suppressed |
| Hydroxyurea | Hydroxyurea | 47 | 15 |
| Potassium Chloride | Potassium Chloride | 47 | 20 |
| Calquence | Acalabrutinib Maleate | 45 | suppressed |
| Lorazepam | Lorazepam | 42 | 26 |
| Lenalidomide | Lenalidomide | 41 | 13 |
| Exemestane | Exemestane | 40 | 15 |
| Acyclovir | Acyclovir | 39 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Xtandi | Enzalutamide | 35 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Fluconazole | Fluconazole | 30 | 17 |
| Methylprednisolone | Methylprednisolone | 30 | 24 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Nystatin | Nystatin | 28 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 18 |
| Furosemide | Furosemide | 25 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 24 | 17 |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Amoxicillin | Amoxicillin | 19 | 13 |
| Omeprazole | Omeprazole | 19 | 11 |
| Tramadol Hcl | Tramadol Hcl | 18 | 14 |
| Bosulif | Bosutinib | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Promacta | Eltrombopag Olamine | 16 | suppressed |
| Dronabinol | Dronabinol | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Everolimus | Everolimus | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,285.12 · 206 records | PFIZER INC. | ADCETRIS, AKEEGA, AKYNZEO, ALPROLIX, ALTUVIIIO, AXTLE, Alecensa, BALVERSA, BELEODAQ, BENEFIX, BESREMI, BOSULIF, BRAFTOVI, BRUKINSA, CABOMETYX, CALQUENCE, CARVYKTI, CYCLOPHOSPHAMIDE, DARZALEX, DATROWAY, DOCIVYX, ELAHERE, ELIGARD, ELIQUIS, ELREXFIO, ENHERTU, EPKINLY, ERLEADA, FOTIVDA, FRINDOVYX, FRUZAQLA, Fabhalta, GIVLAARI, HYMPAVZI, IMBRUVICA, IMFINZI, INJECTAFER, INLYTA, INQOVI, JAKAFI, JATENZO, JAYPIRCA, KEYTRUDA, KISQALI, LIBTAYO, LONSURF, LORBRENA, LUTATHERA, LUTRATE DEPOT, LYNOZYFIC, LYNPARZA, Lenvima, MONJUVI, MYRISK, NERLYNX, NINLARO, NURTEC ODT, Nubeqa, OJJAARA, OPDIVO, ORGOVYX, Onivyde, Optune Gio, PADCEV, PEMAZYRE, PLUVICTO, POSFREA, Polivy, QFITLIA, QINLOCK, REBLOZYL, REVUFORJ, RUBRACA, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, Stivarga, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, Tecentriq, Tecentriq Hybreza, Tivdak, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vanflyta, Vitrakvi, WELIREG, XPOVIO, XTANDI, XYNTHA, Xofigo, Yescarta, ZEPZELCA, ZYNYZ | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bosulif play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error